AXGN - AxoGenAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $19.43 | Open | $19.44 |
| Volume | 195.6K | Market Cap | 747.79M |
| Yield | Last Dividend |
| Trending Report On Dental Care Market By... | 12/19/20 |
| The Dental Care market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, ... | |
| Axogen, Inc. Reports Third Quarter 2020 ... | 10/29/20 |
| ALACHUA, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solution... | |
| AxoGen (AXGN) to Release Quarterly Earni... | 10/21/20 |
| AxoGen (NASDAQ:AXGN) will be announcing its earnings results after the market closes on Thursday, October 29th. Analysts expect the company to announc... | |
| Stem Cell Repair Market 2020-2028 advanc... | 10/14/20 |
| A special process helps isolate the needed cells by using a centrifuge. Those cells are then delivered to the area of injury such as an arthritic knee... | |
| Nerve Repair and Regeneration Market wor... | 10/12/20 |
| According to the new market research report "Nerve Repair and Regeneration Market by Products (Nerve Conduits, Nerve Wraps, Vagus Nerve Stimulation, S... | |
| Unexpected Growth See in Nerve Repair an... | 09/29/20 |
| A report by The Insight Partner's on the global Nerve Repair and Regeneration market discusses the growth of the market in great detail. It discusses ... | |
| Global Nerve Repair and Regeneration Mar... | 08/10/20 |
| DUBLIN--(BUSINESS WIRE)--The "Nerve Repair and Regeneration - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's off... | |
| The Daily Biotech Pulse: Moderna Secures... | 04/17/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 16.) ... | |
| The Daily Biotech Pulse: Roche Obtains F... | 03/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) ... | |
| The Daily Biotech Pulse: NY State Endors... | 03/11/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10)... | |
| Hedge Funds Cashed Out Of AxoGen, Inc. (... | 12/13/19 |
| It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment ... | |
| Q1 2020 Earnings Forecast for AxoGen, In... | 11/14/19 |
| AxoGen, Inc (NASDAQ:AXGN) ??? Stock analysts at Jefferies Financial Group issued their Q1 2020 EPS estimates for AxoGen in a research report issued to... | |
| AxoGen (AXGN) Reports Q2 Loss, Misses Re... | 08/06/19 |
| AxoGen (AXGN) delivered earnings and revenue surprises of 23.08% and -0.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues ... | |
| Earnings Preview: AxoGen (AXGN) Q2 Earni... | 07/30/19 |
| AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with th... | |
| AxoGen Inc (AXGN) Q1 2019 Earnings Call ... | 05/08/19 |
| AXGN earnings call for the period ending March 31, 2019. | |
| AxoGen's (AXGN) CEO Karen Zaderej on Q1 ... | 05/08/19 |
| No summary available. | |
| AxoGen (AXGN) Reports Q1 Loss, Tops Reve... | 05/08/19 |
| AxoGen (AXGN) delivered earnings and revenue surprises of -7.14% and 4.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues ... | |
| AxoGen beats by $0.03, beats on revenue | 05/08/19 |
| No summary available. | |
| AxoGen Q1 2019 Earnings Preview | 05/07/19 |
| No summary available. | |
| Analysts Estimate AxoGen (AXGN) to Repor... | 05/01/19 |
| AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with th... | |
| Small Cap Growth Strategy Q1 '19 Comment... | 04/30/19 |
| No summary available. | |
| Biotech News Recap: Pressure On Shares O... | 04/22/19 |
| No summary available. | |
| Axogen to increase enrollment in late-st... | 04/22/19 |
| No summary available. | |
| AxoGen, Inc. (AXGN) CEO Karen Zaderej on... | 02/26/19 |
| No summary available. | |
| AxoGen, Inc. 2018 Q4 - Results - Earning... | 02/26/19 |
| No summary available. | |
| AxoGen beats by $0.01, misses on revenue | 02/26/19 |
| No summary available. | |
| AxoGen commercial chief bids adieu | 01/16/19 |
| No summary available. | |
| AxoGen commercial chief bids adieu | 01/16/19 |
| No summary available. | |
| Axsome Therapeutics leads healthcare gai... | 01/07/19 |
| No summary available. | |
| Date | 2020-10-29 (AMC) | Est. (EPS/Rev.) | ($0.16)/ 24.52M |
| Actual (EPS/Rev.) | $0.04/ $33.43 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| FEAT. MARVIN GAYE | JOHN KROLIKOWSKI JR | 62.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
